Contraceptive Steroids

Opening Remarks.- Oral Contraceptives and the Occurrence of Disease: Clinical Overview.- Section I Comparative Metabolism, Pharmacokinetics and Pharmacology Steroid Contraceptives.- The Role of Pharmacokinetics in Preclinical Safety Studies of Synthetic Sex Steroids.- Pharmacokinetics of Contraceptive Steroids in Humans.- Species Differences in Metabolism of Contraceptive Steroids.- Steroids of One Class Can Mimic, Inhibit and Potentiate the Biological Effects of Other Steroid Classes when Administered at High Doses.- Mechanism of Action of Estrogen and its Relationship to Toxicological Assessment.- Endocrine Effects of Systemic Steroidal Contraceptives.- Hepatotoxicity of Oral Contraceptives.- New Steroidal Contraceptives, Implications for Toxicological Models.- Summary.- Section II Contraceptive Steroids and Carcinogenicity.- Steroids and Carcinogenesis.- An Assessment of the Toxicological and Carcinogenic Hazards of Contraceptive Steroids.- Estrogens and Carcinogenicity: An Overview of Information from Studies in Experimental Animal Systems.- A Twenty Year Summary of FDA Animal Safety Testing of Contraceptive Steroids.- Section III Effects of Contraceptive Steroids on Coagulation and Lipid Metabolism.- Contraceptive Steroids and Thrombosis.- The Effects of Oral Contraceptive Use on Lipoproteins: Significance for Atherosclerosis.- Cynomolgus Macaques as Models for Evaluating Effects of Contraceptive Steroids on Plasma Lipoproteins and Coronary Artery Atherosclerosis.- Contraceptive Steroid Effects on Serum Lipoproteins and Lipoprotein Subclasses.- Section IV Panel of International Drug Regulatory Agencies.- Panel of International Drug Regulatory Agencies.- Section V Discussion and Advisory Committee Recommendations.- Discussion and Recommendations.- Organizing Committee.